Tavapadon, a drug being tested to treat early Parkinson's disease, has shown great promise in a Phase III trial by AbbVie, the pharmaceutical company announced this week.
Parkinson’s disease, which is lifelong, progressive, and has no cure, occurs when brain cells that make dopamine, a chemical that coordinates movement, stop working or die, according to the Michael J. Fox Foundation for Parkinson’s Research. This causes tremors, slowness, stiffness, and walking and balance problems, among other issues, for the 1 million people affected by the disease in the U.S. and 6 million affected worldwide.
